165,000 Shares in CRISPR Therapeutics AG (NASDAQ:CRSP) Acquired by PBCay One RSC Ltd

PBCay One RSC Ltd bought a new position in shares of CRISPR Therapeutics AG (NASDAQ:CRSP) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 165,000 shares of the company’s stock, valued at approximately $10,329,000. CRISPR Therapeutics makes up about 2.3% of PBCay One RSC Ltd’s holdings, making the stock its 8th largest holding. PBCay One RSC Ltd owned about 0.21% of CRISPR Therapeutics as of its most recent SEC filing.

Other large investors have also recently added to or reduced their stakes in the company. Blue Trust Inc. acquired a new position in CRISPR Therapeutics in the 4th quarter worth approximately $32,000. Bourgeon Capital Management LLC boosted its stake in CRISPR Therapeutics by 1,000.0% in the 4th quarter. Bourgeon Capital Management LLC now owns 550 shares of the company’s stock worth $34,000 after purchasing an additional 500 shares during the period. Principal Securities Inc. acquired a new position in CRISPR Therapeutics in the 4th quarter worth approximately $41,000. TFC Financial Management Inc. boosted its stake in CRISPR Therapeutics by 3,400.0% in the 4th quarter. TFC Financial Management Inc. now owns 700 shares of the company’s stock worth $44,000 after purchasing an additional 680 shares during the period. Finally, Sachetta LLC acquired a new position in CRISPR Therapeutics in the 4th quarter worth approximately $56,000. 69.20% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on CRSP shares. Needham & Company LLC decreased their target price on shares of CRISPR Therapeutics from $90.00 to $88.00 and set a “buy” rating for the company in a research note on Thursday, May 9th. Mizuho raised their price target on shares of CRISPR Therapeutics from $82.00 to $99.00 and gave the company a “buy” rating in a report on Wednesday, March 6th. Barclays dropped their target price on shares of CRISPR Therapeutics from $80.00 to $67.00 and set an “equal weight” rating on the stock in a report on Thursday, May 9th. TheStreet upgraded shares of CRISPR Therapeutics from a “d+” rating to a “c” rating in a report on Friday, February 23rd. Finally, Morgan Stanley lifted their target price on shares of CRISPR Therapeutics from $46.00 to $48.00 and gave the stock an “underweight” rating in a report on Monday, February 26th. Three equities research analysts have rated the stock with a sell rating, seven have issued a hold rating and seven have given a buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $73.46.

Insider Activity

In other news, CEO Samarth Kulkarni sold 19,582 shares of CRISPR Therapeutics stock in a transaction dated Monday, April 15th. The shares were sold at an average price of $59.91, for a total transaction of $1,173,157.62. Following the sale, the chief executive officer now directly owns 208,122 shares in the company, valued at approximately $12,468,589.02. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 4.10% of the stock is owned by company insiders.

CRISPR Therapeutics Stock Performance

NASDAQ:CRSP opened at $63.56 on Monday. The firm’s 50-day moving average is $57.11 and its 200-day moving average is $65.12. CRISPR Therapeutics AG has a 52-week low of $37.55 and a 52-week high of $91.10. The company has a market cap of $5.40 billion, a price-to-earnings ratio of -23.37 and a beta of 1.78.

CRISPR Therapeutics (NASDAQ:CRSP) last issued its earnings results on Wednesday, May 8th. The company reported ($1.43) earnings per share for the quarter, missing the consensus estimate of ($1.35) by ($0.08). The firm had revenue of $0.50 million for the quarter, compared to analyst estimates of $25.53 million. During the same quarter in the prior year, the business posted ($0.67) EPS. The business’s quarterly revenue was down 99.5% compared to the same quarter last year. Equities analysts predict that CRISPR Therapeutics AG will post -5.51 EPS for the current year.

CRISPR Therapeutics Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.